array(1) { [0]=> object(Apache_Solr_Document)#24 (3) { ["_documentBoost":protected]=> bool(false) ["_fields":protected]=> array(6) { ["content_id"]=> array(1) { [0]=> string(15) "DIRECTORY_12548" } ["content_title"]=> array(1) { [0]=> string(16) "VINCENZO FORMICA" } ["description"]=> array(1) { [0]=> string(113969) "

CURRICULUM VITAE

 

PERSONAL DETAILS

Name:                                 Vincenzo

Surname:                           Formica

Date of birth:                     

Place of birth:                  

Home address:                

Professional address:     Policlinico Universitario “Tor Vergata”

V.le Oxford 81, 00133 ROMA

Nationalty:                        Italian

 

EDUCATION

1990-1995 “Orazio Flacco” High School of Potenza. Italy. Humanities subjects. Final Grade: 60/60 “Cum Laude”

1995-2001 “Campus Bio-Medico” University of Rome. Medical School. Medical Degree: 110/110 First class Honours with distinction

2001-2005 Residency training in Medical Oncology, “Tor Vergata” University of Rome, Italy

2010-2014 PhD in Experimental Physiopathology – European label. Thesis title: “Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer”

 

PREGRADUATE RESEARCH EXPERIENCE

1996-1997 Pre -graduate training in laboratory research, National Council of Research, Section of Rome, Prof. M.G. Farace Topics of interest: Gene Therapy for Apolipoportein E

1998-1999 Pre -graduate training in laboratory research, laboratory of Molecular Pathology and Immunochemistry,  “Tor Vergata” University of Rome, Italy. Prof. V. Colizzi Topics of interest: Tissue Inhibitors of Metallo-Proteinases

1999-2000 Pre -graduate training in Clinical Immunology, Institute of Internal Medicine, School of Medicine, University of Rome “La Sapienza”, Prof. A. Afeltra Topics of interest: Rheumatic diseases

2000-2001 Pregraduate training in Pharmacology and Medical Oncology Section, University of Rome, “Tor Vergata” medical school, Italy. Prof. E. Bonmassar and Prof. A. Aquino. Topics of interest: Pharmacological Modulation, In Vivo and In Vitro, of Tumour Antigens: a Tool to improve Cancer Diagnosis and Cancer Therapy Professional skills: performance of several molecular techniques (Real Time-PCR, Western Blot, Northern Blot, Cell Cultures)

 

PROFESSIONAL EXPERIENCE

2001-2003 Resident in Medical Oncology. Pharmacology and Medical Oncology Department. Laboratory based research. “Tor Vergata” University of Rome. Supervised by Prof. E. Bonmassar and Prof. A. Aquino. Topics of interest: Pharmacological Modulation, In Vivo and In Vitro, of Tumour Antigens: a Tool to improve Cancer Diagnosis and Cancer Therapy Professional skills: performance of several molecular techniques (Real Time-PCR, Western Blot, Norther Blot, Cell Cultures)

2002-2003 Emergency Room attachment at “Sandro Pertini” Hospital of Rome

2003-2004 Resident in Medical Oncology. Clinical training. European Institute of Oncology of Milan. Division of Medical Oncology. Prof A. Goldhirsch. Topics of interest: Gastrointestinal Stromal tumors (Investigator in ”Phase III, Randomized, Double Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatinib Mesylate (Gleevec, Glivec®)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor”). Neuroendocrine tumors. (Investigator in ”CROMaNET: Observational study to evaluate Chromogranin A as a marker for diagnosis and follow-up of NET therapy”). Phase I and New Drugs Development in solid tumors. Relationsip between cancer and thromboembolic events. Breast Cancer care.

2004 – 2005 Final year of residency training as Clinical Research Fellow to Professor David Cunningham. Royal Marsden Hospital, London. Activities and topics of interest: Gastrointestinal cancers, Neuroendocrine tumours, Lymphomas. Clinical and research activities: Four outpatient clinics per week. Attendance and presentation of cases at MDM: 3 days a week. Publications: Submission of Case report on CNS toxicity of Capecitabine. Submission of Abstract on Neuroendocrine Tumours, retrospective analysis, GI ASCO 2006. Submission of peer review article on Pancreatic Neuroendocrine Tumours (Advances in Gastrointestinal Cancer).

2006-aprile 2023 Contract as consultant in Medical Oncology at “Tor Vergata” University Hospital of Rome, Italy  

From 2nd May 2023: Tenure-Track Assistant Professor in Medical Oncology, Department of Systems Medicine, Tor Vergata University of Rome

 

TEACHING EXPERIENCE

2006-today Teacher in Medical Oncology, degree of Laboratory Techniques – ‘Tor Vergata’ University of Rome

2007-today Presenter in the annual continuous professional development seminar for nurses of Tor Vergata Hospital “Nursing management of chemotherapy side effect”.

2006-today Clinical tutor for registrar training in medical oncology – ‘Tor Vergata’ University of Rome

2022-today Course Director of Medical Oncology for the Nursing Science degree at the University of Tirana “Our Lady Of Good Counsel”

 

 

PRIZES AND DISTINCTIONS

2001           Acheived 2nd place e in the national Medical Oncology residency entry examination, Italy

2001           Medical degree with First class Honours and Distinction

2004           FULL General Medical Council (UK) registration

2005           Specialization in medical oncology

2014            PhD in Experimental Physiopathology

 

MEDICAL SOCIETY MEMBERSHIP

Associate member of American Society of Clinical Oncology (ASCO)

Associate member of Italian Society of Medical Oncology (AIOM)

Associate member of European Society of Medical Oncology (ESMO)

 

 

LANGUAGES

Italian, English, French

 

EXTRA-CURRICULAR ACTIVITIES/ INTERESTS

Music-keen guitar player

Football

Latin and ancient greek

 

REVIEWER ACTIVITY

Reviewer on request for the following journals:

· British Journal of Clinical Pharmacology

· World Journal of Gastroenterology

· Cancer Chemotherapy and Pharmacology

· Tumor Biology

· Tumori

· Oncology

· Expert Opinion in Therapeutic Targets

 

EDITORIAL BOARD MEMBERSHIP

Member of the editorial board of the following journals:

· World Journal of Gastroenterology

 

ORAL PODIUM/POSTER PRESENTATIONS AT INTERNATIONAL CONFERENCES

• Formica V., et al, Rome, Italy Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells. The 20th International Academy of Tumor Marker Oncology Conference. Tumor Marker in Cancer diagnosis and Therapy June 21-25, 2003, Siena, Italy

• Formica V lecturer at the 2009 congress on granulocyte growth factor “G QUADRO: QUADRO D’INSIEME SULLA GESTIONE DEL TRATTAMENTO DELLA NEUTROPENIA: IMPIEGO DEI G-CSF”. 2009, Rome, Italy

• Formica V lecturer at the 7th congress of “giornate oncologiche dei castelli romani”. Title: adjuvant chemotherapy in gastric cancer. November 29, 2010, Frascati, Italy

• Formica V lecturer at the 2013 Southern Italy Cooperative Oncology Group (SICOG) congress. Title: “future trial in pancreatic cancer. November 25, 2013, Naple, Italy

• Formica V lecturer at the 9th congress of “giornate oncologiche dei castelli romani”. Title: treatment with bevacizumab in breast cancer patients. November 29, 2013, Frascati, Italy

• Fazio N., Goldhirsch A., Zorzino L., Rocca A., Marenghi C., Manzoni S., Formica V., Balduzzi A., Nole`F., De Braud F.“Antiangiogenic effects might correlate with clinical efficacy of very low doses of alpha-2b-Interferon combined with Long Acting Release Octreotide in patients with metastatic neuroendocrine carcinoma”.95th AACR Annual Meeting. March 27-31, 2004. Orange County Convention Center, Orlando, FL. Presentation in Poster Session

• Prete SP, Formica V, Massara MC, Correale P, Francini G, Turriziani M, De Rossi A, Anselmi A, De Vecchis L, Aquino A, Bonmassar E“Drug induced antigenic remodelling: pharmacological basis to develop a highly active anti-tumor immunochemotherapy” 1st “Istituto Superiore di Santà” International meeting on cancer vaccines. April 19-20, 2004. Rome. Presentation in Poster Session

• Orlando L, Colleoni M, Bertolini F, Ghisini R, Sanna G, Formica V, Nolè F, Viale G, Franceschelli L, Goldhirsch A.“Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): Results of a randomized trial in patients (pts) with advanced breast cancer (ABC)” 40th ASCO Annual Meeting, June 5-8, 2004. Ernest N Morial Convention Center. New Orleans, LA.

• Formica V, Norman AR, Cunningham D, Sirohi B, Chong G, Wotherspoon A, Rao S “The new WHO Classification for prognostic assessment of advanced Neuroendocrine Carcinomas (NECs) of the Gastroenteropancreatic (GEP) tract”. Meeting: 2006 Gastrointestinal Cancers Symposium Abstract No: 160

• Formica V, Norman AR, Cunningham D, Sirohi B, Wotherspoon A, Oates J, Chong G “The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract”. Meeting: Meeting: 2006 ASCO Annual Meeting Abstract No: 4092

• E Mannisi, A Caruso, M Coppola, V Formica, I Portarena, P Sileri, F Pallone et al P. 16.3 LEARNING CURVE FOR ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION (EUS-FNA) IN DIAGNOSIS OF ABDOMINAL AND MEDIASTINAL MASS. Digestive and Liver Disease 45, S198S199.2013

• S D'Ugo, P Sileri, V Formica, L Franceschilli, M Roselli, GP Angelucci, M et al Role of metastatic lymph node ratio as a prognostic index in colorectal cancer surgery. European Journal of Surgical Oncology (EJSO) 38 (10), 980. 2012

• M Cossignani, A Caruso, M Coppola, M Cretella, V Formica, I Portarena, F et al ANNALS OF ONCOLOGY 23, 63-63.2012

• P Sileri, SD Ugo, GP Angelucci, L Franceschilli, M D'Eletto, M Capperucci, V Formica V Mo1473 Role of Metastatic Lymph Node Ratio as a Prognostic Index in Colorectal Cancer Surgery. Gastroenterology 142 (5), S-10732012

• V Formica, I Grenga, M Tesauro, V Cereda, MG di Bari, F Guadagni, M Roselli 3063 POSTER Metabolic Syndrome (MetS) in Metastatic (m) Colorectal Cancer (CRC) Patients (pts) Might Delay the Onset of Cachexia. European Journal of Cancer 47, S241.2011

• A Caruso, M Cossignani, M Cretella, M Coppola, V Formica, I Portarena, M .CONTRAST-ENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTERAPY IN PATIENTS WITH LIVER METATASIS: A PRELIMINARY REPORT.ANNALS OF ONCOLOGY 22, v68-v68.2011

• V Formica, I Portarena, M Benassi, V Fiaschetti, GDV Blanco, P Sileri, L .CISPLATIN YIELDS HIGH RATE OF PATHOLOGIC COMPLETE RESPONSE (ypCR) IN COMBINATION WITH CAPECITEBINE AND PELVIC RADIATION IN THE NEOADJUVANT TREATMENT OF RECTAL CANCER.ANNALS OF ONCOLOGY 22, v122-v122.2011

• P Sileri, S D'Ugo, L Franceschilli, GP Angelucci, M Capperucci, E Picone, V Formica. P Adhesional Small Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Longer-Term Study. Gastroenterology 140 (5), S-1029.2011

• P Sileri, L Franceschilli, M D'Eletto, GP Angelucci, S Lazzaro, M Capperucci, V Formica .Ex-Vivo Intra-Arterial Methylene Blue Dye Injection Augments Pathology Lymph-Nodes Harvest Following Colorectal Cancer Surgery. Gastroenterology 140 (5), S-1004.2011

• A Caruso, M Cossignani, M Cretella, M Coppola, E Mannisi, V Formica, P. 1.134: CONTRASTENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTERAPY IN PATIENTS WITH LIVER METATASIS: A PRELIMINARY REPORT. Digestive and Liver Disease 43, S192-S192.2011

• A Caruso, M Cretella, M Cossignani, M Coppola, E Mannisi, P Sileri, V Formica.P. 1.240: EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT.Digestive and Liver Disease 43, S227S228.2011

• M Squadroni, G Di Meglio, F Spada, S Terzi, K Lorizzo, FG De Braud, V Formica. Metronomic capecitabine in advanced well or moderately differentiated neuroendocrine carcinomas. J Clin Oncol (Meeting Abstracts) 28 (15_suppl), e13130. 2010.

• A Caruso, G Del Vecchio Blanco, M Cretella, E Mannisi, V Formica.W1154 EUS Accuracy in Restaging Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Preliminary Report.Gastroenterology 138 (5), S663-S-663.2010

• A Caruso, G Del Vecchio Blanco, M Cretella, E Mannisi, V Formica.P. 108 EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT. Digestive and Liver Disease 42, S141.2010

• V Formica, R Palmirotta, G Del Monte, A Savonarola, G Ludovici. PP119 VEGF polymorphisms as predictors of bevacizumab efficacy in metastatic colorectal cancer.EJC Supplements 7 (4), 17-17.2009

• P Sileri, SD Ugo, V Formica, P Gentileschi, VM Stolfi, N Di Lorenzo, GP. T1553 Access Related Complications After Open and Laparoscopic Colorectal Surgery: A Prospective Study. Gastroenterology 136 (5), A-910-A-910.2009

• P Sileri, GP Angelucci, S D’Ugo, V Formica, P Gentileschi. Access-related complications after open and laparoscopic colorectal surgery: a prospective study. Digestive and Liver Disease 41, S30-S31.2009

• G Del Vecchio Blanco, V Formica, I Portarena, A Caruso, E Mannisi, M Massara .OC3. 06.5 ROLE OF CIRCULATING TUMOUR MARKER CA19. 9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT.Digestive and Liver Disease 40, S53-S54.2008

• BG Del Vecchio, P Sileri, V Formica, I Portarena, R Flori, S Vanni, S Varani .Rectal cancer T staging: Role of endoscopic ultrasound (EUS) and computerized tomographic colonography (CTC). ANNALS OF ONCOLOGY 19, 98-98.2008

• V Formica, I Portarena, V Fiaschetti, G Del Vecchio, M Massara, G Sica, P.Role of circulating tumour marker CA 19.9 and antiangiogenic therapy with bevacizumab in patients with metastatic colorectal cancer on first line systemic treatment.ANNALS OF ONCOLOGY 19, 96-97.2008

• M Roselli, V Formica, E Fossile, R Pellegrino, M Mari, M Rabuffetti, FR.1124 POSTER Feasibility and efficacy of video-assisted home care for cancer patients on chemotherapy (medical care continuity-mcc project). The preliminary Italian experience.European Journal of Cancer Supplements 5 (4), 149.2007

• Di, Grazia A; Di, Fusco D; Laudisi, F; Colella, M; Formica, V; Maresca, C; Franze, E; Pacifico, T; Salvatori, S; Troncone, E; ",OC. 06.6 HEPCIDIN UPREGULATION IN COLORECTAL CANCER ASSOCIATES WITH ACCUMULATION OF REGULATORY MACROPHAGES AND EPITHELIAL–MESENCHYMAL TRANSITION AND CORRELATES WITH PROGRESSION OF THE DISEASE,Digestive and Liver Disease,55,,S101-S102,2023,WB Saunders

 

• Orlandi, Armando; Pinto, Carmine; Calegari, Maria Alessandra; Normanno, Nicola; Maiello, Evaristo; Antonuzzo, Lorenzo; Bordonaro, Roberto; Zampino, M Giulia; Bergamo, Francesca; Tonini, Giuseppe; ",Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study.,,,,,2023,American Society of Clinical Oncology

• Vivaldi, C; Genovesi, V; Nichetti, F; Zanuso, V; Rimini, M; Antonuzzo, L; Formica, V; Pretta, A; Pecora, I; Salani, F; ","P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort",Annals of Oncology,34,,S75-S76,2023,Elsevier

• Di Grazia, A; Franzè, E; Laudisi, F; Diaz, M; Di Fusco, D; Pacifico, T; Formica, V; Stolfi, C; Monteleone, I; Monteleone, G; ",OC. 04.11: HEPCIDIN SILENCING TRIGGERS A TNF-DEPENDENTGASDERMIN E-DRIVEN IMMUNOGENIC CELL DEATH RESPONSE IN COLORECTAL CANCER,Digestive and Liver Disease,56,,S147,2024,WB Saunders

• Puccini, Alberto; Rossini, Daniele; Daprà, Valentina; Schietroma, Francesco; Perazzo, Serena; Ceccarelli, Anna; Zoratto, Federica; Costantini, Manuel; Formica, Vincenzo; Rofei, Michela; ","Clinical outcomes and impact of mismatch repair deficiency (dMMR) in patients with pT4N0 colon cancer (CC): Data from a large, consecutive, multicenter, real-world cohort.",,,,,2024,American Society of Clinical Oncology

• Calegari, Maria Alessandra; Formica, Vincenzo; Zoratto, Federica; Arrivi, Giulia; Torsello, Angela; Polito, Mariam Grazia; Vincenzo, Picone; Emiliani, Alessandra; Cereda, Vittore; Schirripa, Marta; ",Focus on human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (HER2+ mCRC): A real world retrospective analysis.,,,,,2024,American Society of Clinical Oncology

 

 

 

PUBMED PUBLICATIONS (from the latest)

 

  1. Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. PMID: 38691295.
  2. Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster KL, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau HT, Cattrini C, Messina C, Zeghondy J, Morelli C, Loriot Y, Formica V, Patrikidou A. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel). 2024 Apr 11;16(8):1465. doi: 10.3390/cancers16081465. PMID: 38672547; PMCID: PMC11048042.
  3. Riondino S, Rosenfeld R, Formica V, Morelli C, Parisi G, Torino F, Mariotti S, Roselli M. Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events? Cancers (Basel). 2024 Mar 22;16(7):1251. doi: 10.3390/cancers16071251. PMID: 38610929; PMCID: PMC11011072.
  4. Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antoniotti C, Ambrosini M, Piva VM, Nichetti F, Fassan M, Cremolini C, Lonardi S. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20. PMID: 37924647.
  5. Morelli C, Formica V, Bossi P, Rofei M, Guerriero S, Riondino S, Argirò R, Pucci N, Cenci T, Savino L, Rinaldi CG, Garaci F, Orlandi A, D'Angelillo RM, Arkenau HT, Roselli M. Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel). 2023 Sep 25;15(19):4716. doi: 10.3390/cancers15194716. PMID: 37835410; PMCID: PMC10571960.
  6. Vivaldi C, Genovesi V, Ugolini C, Bernardini L, Casadei-Gardini A, Formica V, Salani F, Orsi G, Massa V, Cacciato-Insilla A, Caccese M, Cesario S, Andrikou K, Graziani J, Campani D, Vasile E, Fontanini G, Fornaro L, Masi G. Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology. Oncology. 2024;102(2):157-167. doi: 10.1159/000533406. Epub 2023 Sep 12. PMID: 37699372.
  7. Neri B, Mancone R, Savino L, Schiavone S, Formica V, Pizzi F, Salvatori S, Mossa M, Migliozzi S, Fiorillo M, Morelli C, Moscardelli A, Lolli E, Calabrese E, Sica GS, Monteleone G, Biancone L. Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study. Cancers (Basel). 2023 Jul 26;15(15):3803. doi: 10.3390/cancers15153803. PMID: 37568619; PMCID: PMC10417294.
  8. Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. PMID: 37535876.
  9. Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. PMID: 37452505.
  10. Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell'Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, Dima G, Trovato G, Riondino S, Roselli M, Skoulidis F, Arkenau HT, Cremolini C. Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers (Basel). 2023 Jun 5;15(11):3064. doi: 10.3390/cancers15113064. PMID: 37297026; PMCID: PMC10252545.
  11. Formica V, Riondino S, Morelli C, Guerriero S, D'Amore F, Di Grazia A, Del Vecchio Blanco G, Sica G, Arkenau HT, Monteleone G, Roselli M. HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling. Br J Cancer. 2023 Apr 20. doi: 10.1038/s41416-023-02266-2. Epub ahead of print. PMID: 37081189.
  12. Pirozzi BM, Siragusa L, Baldini G, Pellicciaro M, Grande M, Efrati C, Finizio R, Formica V, Del Vecchio Blanco G, Sica GS. Influence of COVID-19 Pandemic on Colorectal Cancer Presentation, Management and Outcome during the COVID-19 Pandemic. J Clin Med. 2023 Feb 10;12(4):1425. doi: 10.3390/jcm12041425. PMID: 36835958; PMCID: PMC9962694.
  13. Prete AA, Manca P, Messina M, Formica V, Frassineti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. Eur J Cancer. 2023 Mar;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub 2023 Jan 9. PMID: 36753836.
  14. Riondino S, Formica V, Valenzi E, Morelli C, Flaminio V, Portarena I, Torino F, Roselli M. Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? Curr Oncol. 2023 Jan 16;30(1):1220-1231. doi: 10.3390/curroncol30010094. PMID: 36661743; PMCID: PMC9857850.
  15. Morelli C, Formica V, Patrikidou A, Rofei M, Shiu KK, Riondino S, Argirò R, Floris R, Ferlosio A, Orlandi A, Roselli M, Arkenau HT. Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer. J Gastrointest Oncol. 2022 Oct;13(5):2072-2081. doi: 10.21037/jgo-22-217. PMID: 36388663; PMCID: PMC9660047.
  16. Di Grazia A, Di Fusco D, Franzè E, Colella M, Strimpakos G, Salvatori S, Formica V, Laudisi F, Maresca C, Colantoni A, Ortenzi A, Stolfi C, Monteleone I, Monteleone G. Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial-Mesenchymal Transition and Correlates with Progression of the Disease. Cancers (Basel). 2022 Oct 27;14(21):5294. doi: 10.3390/cancers14215294. PMID: 36358713; PMCID: PMC9658525.
  17. Rosenfeld R, Riondino S, Formica V, Torino F, Martuscelli E, Roselli M. MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review. J Pers Med. 2022 Jun 28;12(7):1059. doi: 10.3390/jpm12071059. PMID: 35887556; PMCID: PMC9315470.
  18. Morelli C, Formica V, Roselli M, Arkenau HT. Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer. Gastric Cancer. 2022 Nov;25(6):1123-1124. doi: 10.1007/s10120-022-01320-x. Epub 2022 Jul 2. PMID: 35779127.
  19. Guida AM, Sensi B, Formica V, D'Angelillo RM, Roselli M, Del Vecchio Blanco G, Rossi P, Capolupo GT, Caricato M, Sica GS. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct. 2022 Jun 13;17(1):16. doi: 10.1186/s13062-022-00329-7. PMID: 35698084; PMCID: PMC9195214.
  20. Morelli C, Rofei M, Riondino S, Fraboni D, Torino F, Orlandi A, Tesauro M, Del Vecchio Blanco G, Federici M, Arkenau HT, Formica V, Roselli M. Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. Cancers (Basel). 2022 May 24;14(11):2594. doi: 10.3390/cancers14112594. PMID: 35681576; PMCID: PMC9179512.
  21. Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. PMID: 35666229; PMCID: PMC9426812.
  22. Troncone E, Gadaleta F, Paoluzi OA, Gesuale CM, Formica V, Morelli C, Roselli M, Savino L, Palmieri G, Monteleone G, Del Vecchio Blanco G. Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers (Basel). 2022 Mar 29;14(7):1730. doi: 10.3390/cancers14071730. PMID: 35406502; PMCID: PMC8997048.
  23. Morelli C, Formica V, Doldo E, Riondino S, Rofei M, Vergilii L, Palmieri G, Arkenau HT, Roselli M, Orlandi A. Concordance of Blood-Based and Normal Tissue- Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping. Oncologist. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057. PMID: 35325223; PMCID: PMC9075005.
  24. Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassineti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021 Nov;9(11):e002996. doi: 10.1136/jitc-2021-002996. PMID: 34815354; PMCID: PMC8611452.
  25. Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L. Results of the observational prospective RealFLOT study. BMC Cancer. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. PMID: 34625033; PMCID: PMC8499559.
  26. Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M. KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2021 Sep 20:djab190. doi: 10.1093/jnci/djab190. Epub ahead of print. PMID: 34542636.
  27. Formica V, Nardecchia A, Morelli C, Lucchetti J, Giuliano G, Renzi N, Gallo C, Pellegrino R, Massimiliani V, Serci C, Russo A, Patrikidou A, Arkenau HT, Maiorino L, Tesauro M, Roselli M. Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age. Ann Palliat Med. 2021 Apr;10(4):4252-4261. doi: 10.21037/apm-20-2194. Epub 2021 Apr 1. PMID: 33832305.
  28. Del Vecchio Blanco G, Dwairi R, Giannelli M, Palmieri G, Formica V, Portarena I, Grasso E, Di Iorio L, Benassi M, Giudice EA, Nardecchia A, Rossi P, Roselli M, Sica G, Monteleone G, Paoluzi OA. Clinical care pathway program versus open- access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer. Intern Emerg Med. 2021 Feb 8. doi: 10.1007/s11739-020-02565-z. Epub ahead of print. PMID: 33555540.
  29. Del Vecchio Blanco G, Palmieri G, Giannarelli D, Formica V, Portarena I, Nardecchia A, Troncone E, Benassi M, Giudice E, Anselmo A, Tisone G, Roselli M,Monteleone G, Paoluzi OA. Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. Scand J Gastroenterol. 2021 Feb 4:1-7. doi: 10.1080/00365521.2021.1880628. Epub ahead of print. PMID: 33539716.
  30. Bavetta M, Silvaggio D, Campione E, Sollena P, Formica V, Coletta D, Graziani G, Romano MCP, Roselli M, Peris K, Bianchi L. The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. J Clin Med. 2021 Jan 26;10(3):466. doi: 10.3390/jcm10030466. PMID: 33530427; PMCID: PMC7866016.
  31. Formica V, Lucchetti J, Doldo E, Riondino S, Morelli C, Argirò R, Renzi N, Nitti D, Nardecchia A, Dell'Aquila E, Ferroni P, Guadagni F, Palmieri G, Orlandi A, Roselli M. Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients-The Importance of Tissue/Plasma Discordant Cases. J Clin Med. 2020 Dec 29;10(1):87. doi: 10.3390/jcm10010087. PMID: 33383664; PMCID: PMC7794782.
  32. Formica V, Morelli C, Patrikidou A, Shiu KK, Nardecchia A, Lucchetti J, Roselli M, Arkenau HT. A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit Rev Oncol Hematol. 2021 Jan;157:103173. doi: 10.1016/j.critrevonc.2020.103173. Epub 2020 Nov 18. PMID: 33278677.
  33. Morelli C, Formica V, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M. Irinotecan or Oxaliplatin: Which is the First Move for the Mate? Curr Med Chem. 2020 Oct 16. doi: 10.2174/0929867327666201016124950. Epub ahead of print. PMID: 33069191.
  34. Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A, Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, Formica V, Lencioni M, Falcone A, Vasile E, Fornaro L. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Eur J Cancer. 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub 2020 Aug 1. PMID: 32750500.
  35. Formica V, Minieri M, Bernardini S, Ciotti M, D'Agostini C, Roselli M, Andreoni M, Morelli C, Parisi G, Federici M, Paganelli C, Legramante JM. Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2. Clin Med (Lond). 2020 Jul;20(4):e114-e119. doi: 10.7861/clinmed.2020-0373. Epub 2020 Jul 2. PMID: 32620590; PMCID: PMC7385801.
  36. Formica V, Morelli C, Patrikidou A, Murias C, Butt S, Nardecchia A, Lucchetti J, Renzi N, Shiu KK, Roselli M, Arkenau HT. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. Target Oncol. 2020 Jun;15(3):327-336. doi: 10.1007/s11523-020-00723-z. PMID: 32449030.
  37. Formica V, Morelli C, Patrikidou A, Shiu KK, Roselli M, Arkenau HT. Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy. Gastric Cancer. 2020 Nov;23(6):1107-1108. doi: 10.1007/s10120-020-01084-2. Epub 2020 May 18. PMID: 32424650.
  38. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. Cancers (Basel). 2020 May 6;12(5):1167. doi: 10.3390/cancers12051167. PMID: 32384641;PMCID: PMC7281278.
  39. Sibio S, Di Giorgio A, D'Ugo S, Palmieri G, Cinelli L, Formica V, Sensi B, Bagaglini G, Di Carlo S, Bellato V, Sica GS. Histotype influences emergency presentation and prognosis in colon cancer surgery. Langenbecks Arch Surg. 2019 Nov;404(7):841-851. doi: 10.1007/s00423-019-01826-6. Epub 2019 Nov 23. PMID: 31760472.
  40. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E,Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F,Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I,Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the'BRAF BeCool' study. Eur J Cancer. 2019 Sep;118:121-130. doi:10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19. PMID: 31330487.
  41. Morelli C, Formica V, Pellicori S, Menghi A, Guarino MD, Perricone R,Roselli M. Chemotherapy in Patients with Hereditary Angioedema. Anticancer Res.2018 Dec;38(12):6801-6807. doi: 10.21873/anticanres.13052. PMID: 30504393.
  42. Lucchetti J, Formica V, Giuliano G, Coletta D, Gargano L, Morosetti D,Sileri P, Palmieri G, Roselli M. Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia. Anticancer Res. 2018 Nov;38(11):6561-6564. doi: 10.21873/anticanres.13022. PMID: 30396986.
  43. Legramante JM, Pellicori S, Magrini A, Frittelli T, Formica V, Roselli M.Cancer Patients in the Emergency Department: A "Nightmare" that Might Become a Virtuous Clinical Pathway. Anticancer Res. 2018 Nov;38(11):6387-6391. doi: 10.21873/anticanres.12998. PMID: 30396962.
  44. Formica V, Zaniboni A, Loupakis F, Roselli M. Non-inferiority of three months vs six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? Int J Cancer. 2018 Jun 6. [Epub ahead of print].
  45. Cereda V, Formica V, Roselli M. Issues and promises of bevacizumab in prostate cancer treatment. Expert Opin Biol Ther. 2018 Jun;18(6):707-717.
  46. Formica V, Benassi M, Del Vecchio Blanco G, Doldo E, Martano L, Portarena I, Nardecchia A, Lucchetti J, Morelli C, Giudice E, Rossi P, Anselmo A, Sileri P, Sica G, Orlandi A, Santoni R, Roselli M. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. Med Oncol. 2018 May 2;35(6):83.
  47. Formica V, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M. Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer. Oncotarget. 2017 Dec 17;9(2):2876-2886.
  48. Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, Spila A, D'Alessandro R, Della-Morte D, Ferroni P, Roselli M. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World J Gastroenterol. 2017 Jul 28;23(28):5187-5195.
  49. Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M. Biological and predictive role of ERCC1 polymorphisms in cancer. Crit Rev Oncol Hematol. 2017 Mar;111:133-143.
  50. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017 Apr;49(4):338-358.
  51. Ferroni P, Formica V, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M. Prognostic value of glycated hemoglobin in colorectal cancer. World J Gastroenterol. 2016 Dec 7;22(45):9984-9993.
  52. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretti M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2017 Mar 1;28(3):555-561.
  53. Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pellicori S, Cereda V, Russo A, Riondino S, Guadagni F, Roselli M. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomark. 2016 Sep 26;17(3):335-345.
  54. Riondino S, Guadagni F, Formica V, Ferroni P, Roselli M. Gender Differences in Cancer-associated Venous Thromboembolism. Curr Med Chem. 2017;24(24):2589-2601.
  55. Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016 May 19;5(7):e1188243.
  56. Fiaschetti V, Liberto V, Claroni G, Loreni G, Formica V, Roselli M, Mauriello A, Floris R. Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature. Radiol Case Rep. 2016 May 14;11(3):255-9.
  57. Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist. 2016 Sep;21(9):1041-9.
  58. Formica V, Zaniboni A. Response from Drs. Formica/Zaniboni to Dr. Milano. Cancer Chemother Pharmacol. 2016 Aug;78(2):247.
  59. Zaniboni A, Formica V. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol. 2016 Aug;78(2):233-44.
  60. Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):219-28. doi: 10.4103/0971-5851.171542. PMID: 26811591; PMCID: PMC4711220.
  61. Formica V, Formica D, Formica G. The 'death pace' in the CO.17 trial. Eur J Cancer. 2016 Jan;53:1-4. doi: 10.1016/j.ejca.2015.09.020. Epub 2015 Dec 11. PMID: 26688001.
  62. Riondino S, Ferroni P, Spila A, Alessandroni J, D'Alessandro R, Formica V, Della-Morte D, Palmirotta R, Nanni U, Roselli M, Guadagni F. Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle. Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):291-9. PMID: 26543078.
  63. Lisanti A, Formica V, Ianni F, Albertini B, Marinozzi M, Sardella R, Natalini B. Antioxidant activity of phenolic extracts from different cultivars of Italian onion (Allium cepa) and relative human immune cell proliferative induction. Pharm Biol. 2016;54(5):799-806. doi: 10.3109/13880209.2015.1080733. Epub 2015 Oct 9. PMID: 26452395.
  64. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. PMID: 26446234; PMCID: PMC4718427.
  65. Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V, Guadagni F, Roselli M. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thromb Haemost. 2016 Jan;115(1):143-51. doi: 10.1160/TH15-03-0259. Epub 2015 Sep 3. PMID: 26336029.
  66. Del Vecchio Blanco G, Coppola M, Mannisi E, Bevivino G, Formica V, Portarena I, Romeo S, Sileri P, Roselli M, Pallone F, Paoluzi OA. Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass. Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1045-51.
  67. Cereda V, Formica V, Menghi A, Pellicori S, Roselli M.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. Expert Opin Investig Drugs. 2015 Jul;24(7):929-47.
  68. Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol. 2015 Mar 14;21(10):2871-4.
  69. Formica V, Montefusco E, Roselli M. Are there alternative ways to quantify the real benefit of novel agents in oncology? -the 'death pace'.Cancer Biol Ther. 2015;16(2):187-8.
  70. Formica V, Cereda V, Nardecchia A, Tesauro M, Roselli M. Immune reaction and colorectal cancer: friends or foes? World J Gastroenterol. 2014 Sep 21;20(35):12407-19.
  71. Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014 Sep;31(9):166.
  72. Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, Valente MG, Vergati M, Guadagni F, Roselli M. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.Int J Cancer. 2015 Mar 1;136(5):1234-40.
  73. Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer relationship with clinical outcome.Anticancer Res. 2014 Mar;34(3):1153-61.
  74. Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Expert Opin Investig Drugs. 2014 Apr;23(4):469-87.
  75. Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013 Oct 1;2(10):e27025.
  76. Vincenzo F, Manfredi T, Carmine C, Mario R. CD26: a multi-purpose pharmacological target. Curr Clin Pharmacol. 2014 May;9(2):157-64. doi: 10.2174/1574884708666131111201654. PMID: 24219003.
  77. Formica V, Cereda V, di Bari MG, Grenga I, Tesauro M, Raffaele P, Ferroni P, Guadagni F, Roselli M.Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Med Oncol. 2013 Dec;30(4):743.
  78. Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirotta R, Formica V, Ludovici G, Laudisi A, De Marchis ML, La Farina F, Russo A, Guadagni F. TNF-a gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Ann Oncol. 2013 Oct;24(10):2571-5.
  79. Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, Formica V, Vergati M, Guadagni F. Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. Thromb Haemost. 2012 Dec;108(6):1243-5.
  80. Formica V, Vasile E, Roselli M. Family history of cancer in patients with gastric cancer. J Clin Oncol. 2012 Sep 1;30(25):3151-2; author reply 3152-3.
  81. Palmirotta R, Ludovici G, De Marchis ML, Leone B, Formica V, Ettorre GM, Cavaliere F, Della-Morte D, Ferroni P, Roselli M, Guadagni F.A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. In Vivo. 2012 Jul;26(4):537-47.
  82. Sileri P, D'Ugo S, del Vecchio Blanco G, Lolli E, Franceschilli L, Formica V, Anemona L, De Luca C, Gaspari AL. Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case. Int J Surg Case Rep. 2012;3(8):3858.
  83. Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, Massimiani G, Palmirotta R, Guadagni F, Roselli M. Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis. 2012 Dec;27(12):1561-7.
  84. Formica V, Tesauro M, Cardillo C, Roselli M. Insulinemia and the risk of breast cancer and its relapse. Diabetes Obes Metab. 2012 Apr 26.
  85. Formica V, Martano L, Palmirotta R, Ferroni P, Del Monte G, Guadagni F, Roselli M. VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. Ann Oncol. 2011 Aug;22(8):1928-9.
  86. Formica V, Del Monte G, Giacchetti I, Grenga I, Giaquinto S, Fini M, Roselli M. Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience. Integr Cancer Ther. 2011 Jun;10(2):119-26.
  87. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis. 2011 Feb;26(2):143-51.
  88. Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. Anticancer Res. 2010 Nov;30(11):4721-30.
  89. Pellegrino R, Formica V, Portarena I, Mariotti S, Grenga I, Del Monte G, Roselli M. Caregiver distress in the early phases of cancer. Anticancer Res. 2010 Nov;30(11):4657-63.
  90. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol. 2009;122(4):193-9.
  91. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark. 2009;5(4):167-75.
  92. Palmirotta R, Savonarola A, Formica V, Ludovici G, Del Monte G, Roselli M, Guadagni F. A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Res. 2009 Aug;29(8):3369-74.
  93. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009 Aug;29(8):3321-7.
  94. Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol. 2010 Jan;8(1):102-13.
  95. Formica V, Fossile E, Pellegrino R, Fatale M, Mari M, Rabuffetti M, Benedetto FR, Visconti G, Bollero E, Roselli M. The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience. Support Care Cancer. 2009 May;17(5):471-8.
  96. Masala S, Manenti G, Roselli M, Mammucari M, Bartolucci DA, Formica V, Massari F, Simonetti G. Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol. Anticancer Res. 2007 Nov-Dec;27(6C):4259-62.
  97. Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V, Roselli M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 2007 Sep-Oct;27(5A):3147-62.
  98. Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology. 2006;71(3-4):176-84.
  99. Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V, Roselli M. Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo. 2007 Mar-Apr;21(2):147-61.
  100. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007 Apr 23;96(8):1178-82
  101. Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol. 2006 Jul;17(7):1174-5.
  102. Formica V, Leary A, Cunningham D, Chua YJ. 5-Fluorouracil can cross Brain Blood Barrier (BBB) and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol. 2006 Aug;58(2):276-8.
  103. De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection? J Clin Oncol. 2005 Sep 1;23(25):6274-5
  104. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005 Jul 15;175(2):820-8.
  105. De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nole F, Fazio N, Formica V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain Support Care Cancer. 2005 Mar;13(3):194-5.
  106. Bonmassar L, Massara MC, Cottarelli A, Aquino A, Formica V, Prete SP, Lacal PM, Marchetti P, Concolino F, Faraoni I, D'Atri S. Preclinical studies on detection of circulating melanoma cells in patients: telomerase as a recognition marker of malignancy J Chemother. 2004 Oct;16(5):479-86.
  107. Curigliano G, Rigo R, Colleoni M, Nolè F, Formica V, Orlando L, Cardillo A, Torrisi R, Manzoni S, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant Therapy for Very Young Women With Breast Cancer: Response According to Biologic and Endocrine Features. Clin Breast Cancer. 2004 Jun;5(2):125-30. Review.
  108. Aquino A, Formica V, Prete SP, Correale PP, Massara M.C, Turriziani M, De Vecchis L, Bonmassar E. Drug induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res. 2004 Apr;49(5):383-96. Review.
  109. Aquino A, Prete SP, Balduzzi A, Fossile E, Formica V, Torino F, Bonmassar L, Di Giacomo A, Cappelletti D, Cardillo A, Bonmassar E, Graziani G. A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report. J Chemother. 14:412-416, 2002.
  110. Aquino A, Prete S.P, Balduzzi A, Formica V, Fossile E, Bonmassar L, Concolino F, Bonmassar E, Graziani G. Treatment of peripheral blood with Staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. Int J Cancer. 100:119-121, 2002.

 

CURRICULUM VITAE

 

PERSONAL DETAILS

Name:                                 Vincenzo

Surname:                           Formica

Date of birth:                     

Place of birth:                  

Home address:                

Professional address:     Policlinico Universitario “Tor Vergata”

V.le Oxford 81, 00133 ROMA

Nationalty:                        Italian

 

EDUCATION

1990-1995 “Orazio Flacco” High School of Potenza. Italy. Humanities subjects. Final Grade: 60/60 “Cum Laude”

1995-2001 “Campus Bio-Medico” University of Rome. Medical School. Medical Degree: 110/110 First class Honours with distinction

2001-2005 Residency training in Medical Oncology, “Tor Vergata” University of Rome, Italy

2010-2014 PhD in Experimental Physiopathology – European label. Thesis title: “Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer”

 

PREGRADUATE RESEARCH EXPERIENCE

1996-1997 Pre -graduate training in laboratory research, National Council of Research, Section of Rome, Prof. M.G. Farace Topics of interest: Gene Therapy for Apolipoportein E

1998-1999 Pre -graduate training in laboratory research, laboratory of Molecular Pathology and Immunochemistry,  “Tor Vergata” University of Rome, Italy. Prof. V. Colizzi Topics of interest: Tissue Inhibitors of Metallo-Proteinases

1999-2000 Pre -graduate training in Clinical Immunology, Institute of Internal Medicine, School of Medicine, University of Rome “La Sapienza”, Prof. A. Afeltra Topics of interest: Rheumatic diseases

2000-2001 Pregraduate training in Pharmacology and Medical Oncology Section, University of Rome, “Tor Vergata” medical school, Italy. Prof. E. Bonmassar and Prof. A. Aquino. Topics of interest: Pharmacological Modulation, In Vivo and In Vitro, of Tumour Antigens: a Tool to improve Cancer Diagnosis and Cancer Therapy Professional skills: performance of several molecular techniques (Real Time-PCR, Western Blot, Northern Blot, Cell Cultures)

 

PROFESSIONAL EXPERIENCE

2001-2003 Resident in Medical Oncology. Pharmacology and Medical Oncology Department. Laboratory based research. “Tor Vergata” University of Rome. Supervised by Prof. E. Bonmassar and Prof. A. Aquino. Topics of interest: Pharmacological Modulation, In Vivo and In Vitro, of Tumour Antigens: a Tool to improve Cancer Diagnosis and Cancer Therapy Professional skills: performance of several molecular techniques (Real Time-PCR, Western Blot, Norther Blot, Cell Cultures)

2002-2003 Emergency Room attachment at “Sandro Pertini” Hospital of Rome

2003-2004 Resident in Medical Oncology. Clinical training. European Institute of Oncology of Milan. Division of Medical Oncology. Prof A. Goldhirsch. Topics of interest: Gastrointestinal Stromal tumors (Investigator in ”Phase III, Randomized, Double Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatinib Mesylate (Gleevec, Glivec®)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor”). Neuroendocrine tumors. (Investigator in ”CROMaNET: Observational study to evaluate Chromogranin A as a marker for diagnosis and follow-up of NET therapy”). Phase I and New Drugs Development in solid tumors. Relationsip between cancer and thromboembolic events. Breast Cancer care.

2004 – 2005 Final year of residency training as Clinical Research Fellow to Professor David Cunningham. Royal Marsden Hospital, London. Activities and topics of interest: Gastrointestinal cancers, Neuroendocrine tumours, Lymphomas. Clinical and research activities: Four outpatient clinics per week. Attendance and presentation of cases at MDM: 3 days a week. Publications: Submission of Case report on CNS toxicity of Capecitabine. Submission of Abstract on Neuroendocrine Tumours, retrospective analysis, GI ASCO 2006. Submission of peer review article on Pancreatic Neuroendocrine Tumours (Advances in Gastrointestinal Cancer).

2006-aprile 2023 Contract as consultant in Medical Oncology at “Tor Vergata” University Hospital of Rome, Italy  

From 2nd May 2023: Tenure-Track Assistant Professor in Medical Oncology, Department of Systems Medicine, Tor Vergata University of Rome

 

TEACHING EXPERIENCE

2006-today Teacher in Medical Oncology, degree of Laboratory Techniques – ‘Tor Vergata’ University of Rome

2007-today Presenter in the annual continuous professional development seminar for nurses of Tor Vergata Hospital “Nursing management of chemotherapy side effect”.

2006-today Clinical tutor for registrar training in medical oncology – ‘Tor Vergata’ University of Rome

2022-today Course Director of Medical Oncology for the Nursing Science degree at the University of Tirana “Our Lady Of Good Counsel”

 

 

PRIZES AND DISTINCTIONS

2001           Acheived 2nd place e in the national Medical Oncology residency entry examination, Italy

2001           Medical degree with First class Honours and Distinction

2004           FULL General Medical Council (UK) registration

2005           Specialization in medical oncology

2014            PhD in Experimental Physiopathology

 

MEDICAL SOCIETY MEMBERSHIP

Associate member of American Society of Clinical Oncology (ASCO)

Associate member of Italian Society of Medical Oncology (AIOM)

Associate member of European Society of Medical Oncology (ESMO)

 

 

LANGUAGES

Italian, English, French

 

EXTRA-CURRICULAR ACTIVITIES/ INTERESTS

Music-keen guitar player

Football

Latin and ancient greek

 

REVIEWER ACTIVITY

Reviewer on request for the following journals:

· British Journal of Clinical Pharmacology

· World Journal of Gastroenterology

· Cancer Chemotherapy and Pharmacology

· Tumor Biology

· Tumori

· Oncology

· Expert Opinion in Therapeutic Targets

 

EDITORIAL BOARD MEMBERSHIP

Member of the editorial board of the following journals:

· World Journal of Gastroenterology

 

ORAL PODIUM/POSTER PRESENTATIONS AT INTERNATIONAL CONFERENCES

• Formica V., et al, Rome, Italy Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells. The 20th International Academy of Tumor Marker Oncology Conference. Tumor Marker in Cancer diagnosis and Therapy June 21-25, 2003, Siena, Italy

• Formica V lecturer at the 2009 congress on granulocyte growth factor “G QUADRO: QUADRO D’INSIEME SULLA GESTIONE DEL TRATTAMENTO DELLA NEUTROPENIA: IMPIEGO DEI G-CSF”. 2009, Rome, Italy

• Formica V lecturer at the 7th congress of “giornate oncologiche dei castelli romani”. Title: adjuvant chemotherapy in gastric cancer. November 29, 2010, Frascati, Italy

• Formica V lecturer at the 2013 Southern Italy Cooperative Oncology Group (SICOG) congress. Title: “future trial in pancreatic cancer. November 25, 2013, Naple, Italy

• Formica V lecturer at the 9th congress of “giornate oncologiche dei castelli romani”. Title: treatment with bevacizumab in breast cancer patients. November 29, 2013, Frascati, Italy

• Fazio N., Goldhirsch A., Zorzino L., Rocca A., Marenghi C., Manzoni S., Formica V., Balduzzi A., Nole`F., De Braud F.“Antiangiogenic effects might correlate with clinical efficacy of very low doses of alpha-2b-Interferon combined with Long Acting Release Octreotide in patients with metastatic neuroendocrine carcinoma”.95th AACR Annual Meeting. March 27-31, 2004. Orange County Convention Center, Orlando, FL. Presentation in Poster Session

• Prete SP, Formica V, Massara MC, Correale P, Francini G, Turriziani M, De Rossi A, Anselmi A, De Vecchis L, Aquino A, Bonmassar E“Drug induced antigenic remodelling: pharmacological basis to develop a highly active anti-tumor immunochemotherapy” 1st “Istituto Superiore di Santà” International meeting on cancer vaccines. April 19-20, 2004. Rome. Presentation in Poster Session

• Orlando L, Colleoni M, Bertolini F, Ghisini R, Sanna G, Formica V, Nolè F, Viale G, Franceschelli L, Goldhirsch A.“Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): Results of a randomized trial in patients (pts) with advanced breast cancer (ABC)” 40th ASCO Annual Meeting, June 5-8, 2004. Ernest N Morial Convention Center. New Orleans, LA.

• Formica V, Norman AR, Cunningham D, Sirohi B, Chong G, Wotherspoon A, Rao S “The new WHO Classification for prognostic assessment of advanced Neuroendocrine Carcinomas (NECs) of the Gastroenteropancreatic (GEP) tract”. Meeting: 2006 Gastrointestinal Cancers Symposium Abstract No: 160

• Formica V, Norman AR, Cunningham D, Sirohi B, Wotherspoon A, Oates J, Chong G “The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract”. Meeting: Meeting: 2006 ASCO Annual Meeting Abstract No: 4092

• E Mannisi, A Caruso, M Coppola, V Formica, I Portarena, P Sileri, F Pallone et al P. 16.3 LEARNING CURVE FOR ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION (EUS-FNA) IN DIAGNOSIS OF ABDOMINAL AND MEDIASTINAL MASS. Digestive and Liver Disease 45, S198S199.2013

• S D'Ugo, P Sileri, V Formica, L Franceschilli, M Roselli, GP Angelucci, M et al Role of metastatic lymph node ratio as a prognostic index in colorectal cancer surgery. European Journal of Surgical Oncology (EJSO) 38 (10), 980. 2012

• M Cossignani, A Caruso, M Coppola, M Cretella, V Formica, I Portarena, F et al ANNALS OF ONCOLOGY 23, 63-63.2012

• P Sileri, SD Ugo, GP Angelucci, L Franceschilli, M D'Eletto, M Capperucci, V Formica V Mo1473 Role of Metastatic Lymph Node Ratio as a Prognostic Index in Colorectal Cancer Surgery. Gastroenterology 142 (5), S-10732012

• V Formica, I Grenga, M Tesauro, V Cereda, MG di Bari, F Guadagni, M Roselli 3063 POSTER Metabolic Syndrome (MetS) in Metastatic (m) Colorectal Cancer (CRC) Patients (pts) Might Delay the Onset of Cachexia. European Journal of Cancer 47, S241.2011

• A Caruso, M Cossignani, M Cretella, M Coppola, V Formica, I Portarena, M .CONTRAST-ENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTERAPY IN PATIENTS WITH LIVER METATASIS: A PRELIMINARY REPORT.ANNALS OF ONCOLOGY 22, v68-v68.2011

• V Formica, I Portarena, M Benassi, V Fiaschetti, GDV Blanco, P Sileri, L .CISPLATIN YIELDS HIGH RATE OF PATHOLOGIC COMPLETE RESPONSE (ypCR) IN COMBINATION WITH CAPECITEBINE AND PELVIC RADIATION IN THE NEOADJUVANT TREATMENT OF RECTAL CANCER.ANNALS OF ONCOLOGY 22, v122-v122.2011

• P Sileri, S D'Ugo, L Franceschilli, GP Angelucci, M Capperucci, E Picone, V Formica. P Adhesional Small Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Longer-Term Study. Gastroenterology 140 (5), S-1029.2011

• P Sileri, L Franceschilli, M D'Eletto, GP Angelucci, S Lazzaro, M Capperucci, V Formica .Ex-Vivo Intra-Arterial Methylene Blue Dye Injection Augments Pathology Lymph-Nodes Harvest Following Colorectal Cancer Surgery. Gastroenterology 140 (5), S-1004.2011

• A Caruso, M Cossignani, M Cretella, M Coppola, E Mannisi, V Formica, P. 1.134: CONTRASTENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTERAPY IN PATIENTS WITH LIVER METATASIS: A PRELIMINARY REPORT. Digestive and Liver Disease 43, S192-S192.2011

• A Caruso, M Cretella, M Cossignani, M Coppola, E Mannisi, P Sileri, V Formica.P. 1.240: EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT.Digestive and Liver Disease 43, S227S228.2011

• M Squadroni, G Di Meglio, F Spada, S Terzi, K Lorizzo, FG De Braud, V Formica. Metronomic capecitabine in advanced well or moderately differentiated neuroendocrine carcinomas. J Clin Oncol (Meeting Abstracts) 28 (15_suppl), e13130. 2010.

• A Caruso, G Del Vecchio Blanco, M Cretella, E Mannisi, V Formica.W1154 EUS Accuracy in Restaging Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Preliminary Report.Gastroenterology 138 (5), S663-S-663.2010

• A Caruso, G Del Vecchio Blanco, M Cretella, E Mannisi, V Formica.P. 108 EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT. Digestive and Liver Disease 42, S141.2010

• V Formica, R Palmirotta, G Del Monte, A Savonarola, G Ludovici. PP119 VEGF polymorphisms as predictors of bevacizumab efficacy in metastatic colorectal cancer.EJC Supplements 7 (4), 17-17.2009

• P Sileri, SD Ugo, V Formica, P Gentileschi, VM Stolfi, N Di Lorenzo, GP. T1553 Access Related Complications After Open and Laparoscopic Colorectal Surgery: A Prospective Study. Gastroenterology 136 (5), A-910-A-910.2009

• P Sileri, GP Angelucci, S D’Ugo, V Formica, P Gentileschi. Access-related complications after open and laparoscopic colorectal surgery: a prospective study. Digestive and Liver Disease 41, S30-S31.2009

• G Del Vecchio Blanco, V Formica, I Portarena, A Caruso, E Mannisi, M Massara .OC3. 06.5 ROLE OF CIRCULATING TUMOUR MARKER CA19. 9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT.Digestive and Liver Disease 40, S53-S54.2008

• BG Del Vecchio, P Sileri, V Formica, I Portarena, R Flori, S Vanni, S Varani .Rectal cancer T staging: Role of endoscopic ultrasound (EUS) and computerized tomographic colonography (CTC). ANNALS OF ONCOLOGY 19, 98-98.2008

• V Formica, I Portarena, V Fiaschetti, G Del Vecchio, M Massara, G Sica, P.Role of circulating tumour marker CA 19.9 and antiangiogenic therapy with bevacizumab in patients with metastatic colorectal cancer on first line systemic treatment.ANNALS OF ONCOLOGY 19, 96-97.2008

• M Roselli, V Formica, E Fossile, R Pellegrino, M Mari, M Rabuffetti, FR.1124 POSTER Feasibility and efficacy of video-assisted home care for cancer patients on chemotherapy (medical care continuity-mcc project). The preliminary Italian experience.European Journal of Cancer Supplements 5 (4), 149.2007

• Di, Grazia A; Di, Fusco D; Laudisi, F; Colella, M; Formica, V; Maresca, C; Franze, E; Pacifico, T; Salvatori, S; Troncone, E; ",OC. 06.6 HEPCIDIN UPREGULATION IN COLORECTAL CANCER ASSOCIATES WITH ACCUMULATION OF REGULATORY MACROPHAGES AND EPITHELIAL–MESENCHYMAL TRANSITION AND CORRELATES WITH PROGRESSION OF THE DISEASE,Digestive and Liver Disease,55,,S101-S102,2023,WB Saunders

 

• Orlandi, Armando; Pinto, Carmine; Calegari, Maria Alessandra; Normanno, Nicola; Maiello, Evaristo; Antonuzzo, Lorenzo; Bordonaro, Roberto; Zampino, M Giulia; Bergamo, Francesca; Tonini, Giuseppe; ",Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study.,,,,,2023,American Society of Clinical Oncology

• Vivaldi, C; Genovesi, V; Nichetti, F; Zanuso, V; Rimini, M; Antonuzzo, L; Formica, V; Pretta, A; Pecora, I; Salani, F; ","P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort",Annals of Oncology,34,,S75-S76,2023,Elsevier

• Di Grazia, A; Franzè, E; Laudisi, F; Diaz, M; Di Fusco, D; Pacifico, T; Formica, V; Stolfi, C; Monteleone, I; Monteleone, G; ",OC. 04.11: HEPCIDIN SILENCING TRIGGERS A TNF-DEPENDENTGASDERMIN E-DRIVEN IMMUNOGENIC CELL DEATH RESPONSE IN COLORECTAL CANCER,Digestive and Liver Disease,56,,S147,2024,WB Saunders

• Puccini, Alberto; Rossini, Daniele; Daprà, Valentina; Schietroma, Francesco; Perazzo, Serena; Ceccarelli, Anna; Zoratto, Federica; Costantini, Manuel; Formica, Vincenzo; Rofei, Michela; ","Clinical outcomes and impact of mismatch repair deficiency (dMMR) in patients with pT4N0 colon cancer (CC): Data from a large, consecutive, multicenter, real-world cohort.",,,,,2024,American Society of Clinical Oncology

• Calegari, Maria Alessandra; Formica, Vincenzo; Zoratto, Federica; Arrivi, Giulia; Torsello, Angela; Polito, Mariam Grazia; Vincenzo, Picone; Emiliani, Alessandra; Cereda, Vittore; Schirripa, Marta; ",Focus on human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (HER2+ mCRC): A real world retrospective analysis.,,,,,2024,American Society of Clinical Oncology

 

 

 

PUBMED PUBLICATIONS (from the latest)

 

  1. Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. PMID: 38691295.
  2. Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster KL, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau HT, Cattrini C, Messina C, Zeghondy J, Morelli C, Loriot Y, Formica V, Patrikidou A. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel). 2024 Apr 11;16(8):1465. doi: 10.3390/cancers16081465. PMID: 38672547; PMCID: PMC11048042.
  3. Riondino S, Rosenfeld R, Formica V, Morelli C, Parisi G, Torino F, Mariotti S, Roselli M. Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events? Cancers (Basel). 2024 Mar 22;16(7):1251. doi: 10.3390/cancers16071251. PMID: 38610929; PMCID: PMC11011072.
  4. Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antoniotti C, Ambrosini M, Piva VM, Nichetti F, Fassan M, Cremolini C, Lonardi S. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20. PMID: 37924647.
  5. Morelli C, Formica V, Bossi P, Rofei M, Guerriero S, Riondino S, Argirò R, Pucci N, Cenci T, Savino L, Rinaldi CG, Garaci F, Orlandi A, D'Angelillo RM, Arkenau HT, Roselli M. Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel). 2023 Sep 25;15(19):4716. doi: 10.3390/cancers15194716. PMID: 37835410; PMCID: PMC10571960.
  6. Vivaldi C, Genovesi V, Ugolini C, Bernardini L, Casadei-Gardini A, Formica V, Salani F, Orsi G, Massa V, Cacciato-Insilla A, Caccese M, Cesario S, Andrikou K, Graziani J, Campani D, Vasile E, Fontanini G, Fornaro L, Masi G. Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology. Oncology. 2024;102(2):157-167. doi: 10.1159/000533406. Epub 2023 Sep 12. PMID: 37699372.
  7. Neri B, Mancone R, Savino L, Schiavone S, Formica V, Pizzi F, Salvatori S, Mossa M, Migliozzi S, Fiorillo M, Morelli C, Moscardelli A, Lolli E, Calabrese E, Sica GS, Monteleone G, Biancone L. Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study. Cancers (Basel). 2023 Jul 26;15(15):3803. doi: 10.3390/cancers15153803. PMID: 37568619; PMCID: PMC10417294.
  8. Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. PMID: 37535876.
  9. Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. PMID: 37452505.
  10. Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell'Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, Dima G, Trovato G, Riondino S, Roselli M, Skoulidis F, Arkenau HT, Cremolini C. Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers (Basel). 2023 Jun 5;15(11):3064. doi: 10.3390/cancers15113064. PMID: 37297026; PMCID: PMC10252545.
  11. Formica V, Riondino S, Morelli C, Guerriero S, D'Amore F, Di Grazia A, Del Vecchio Blanco G, Sica G, Arkenau HT, Monteleone G, Roselli M. HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling. Br J Cancer. 2023 Apr 20. doi: 10.1038/s41416-023-02266-2. Epub ahead of print. PMID: 37081189.
  12. Pirozzi BM, Siragusa L, Baldini G, Pellicciaro M, Grande M, Efrati C, Finizio R, Formica V, Del Vecchio Blanco G, Sica GS. Influence of COVID-19 Pandemic on Colorectal Cancer Presentation, Management and Outcome during the COVID-19 Pandemic. J Clin Med. 2023 Feb 10;12(4):1425. doi: 10.3390/jcm12041425. PMID: 36835958; PMCID: PMC9962694.
  13. Prete AA, Manca P, Messina M, Formica V, Frassineti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. Eur J Cancer. 2023 Mar;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub 2023 Jan 9. PMID: 36753836.
  14. Riondino S, Formica V, Valenzi E, Morelli C, Flaminio V, Portarena I, Torino F, Roselli M. Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? Curr Oncol. 2023 Jan 16;30(1):1220-1231. doi: 10.3390/curroncol30010094. PMID: 36661743; PMCID: PMC9857850.
  15. Morelli C, Formica V, Patrikidou A, Rofei M, Shiu KK, Riondino S, Argirò R, Floris R, Ferlosio A, Orlandi A, Roselli M, Arkenau HT. Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer. J Gastrointest Oncol. 2022 Oct;13(5):2072-2081. doi: 10.21037/jgo-22-217. PMID: 36388663; PMCID: PMC9660047.
  16. Di Grazia A, Di Fusco D, Franzè E, Colella M, Strimpakos G, Salvatori S, Formica V, Laudisi F, Maresca C, Colantoni A, Ortenzi A, Stolfi C, Monteleone I, Monteleone G. Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial-Mesenchymal Transition and Correlates with Progression of the Disease. Cancers (Basel). 2022 Oct 27;14(21):5294. doi: 10.3390/cancers14215294. PMID: 36358713; PMCID: PMC9658525.
  17. Rosenfeld R, Riondino S, Formica V, Torino F, Martuscelli E, Roselli M. MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review. J Pers Med. 2022 Jun 28;12(7):1059. doi: 10.3390/jpm12071059. PMID: 35887556; PMCID: PMC9315470.
  18. Morelli C, Formica V, Roselli M, Arkenau HT. Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer. Gastric Cancer. 2022 Nov;25(6):1123-1124. doi: 10.1007/s10120-022-01320-x. Epub 2022 Jul 2. PMID: 35779127.
  19. Guida AM, Sensi B, Formica V, D'Angelillo RM, Roselli M, Del Vecchio Blanco G, Rossi P, Capolupo GT, Caricato M, Sica GS. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct. 2022 Jun 13;17(1):16. doi: 10.1186/s13062-022-00329-7. PMID: 35698084; PMCID: PMC9195214.
  20. Morelli C, Rofei M, Riondino S, Fraboni D, Torino F, Orlandi A, Tesauro M, Del Vecchio Blanco G, Federici M, Arkenau HT, Formica V, Roselli M. Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. Cancers (Basel). 2022 May 24;14(11):2594. doi: 10.3390/cancers14112594. PMID: 35681576; PMCID: PMC9179512.
  21. Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. PMID: 35666229; PMCID: PMC9426812.
  22. Troncone E, Gadaleta F, Paoluzi OA, Gesuale CM, Formica V, Morelli C, Roselli M, Savino L, Palmieri G, Monteleone G, Del Vecchio Blanco G. Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers (Basel). 2022 Mar 29;14(7):1730. doi: 10.3390/cancers14071730. PMID: 35406502; PMCID: PMC8997048.
  23. Morelli C, Formica V, Doldo E, Riondino S, Rofei M, Vergilii L, Palmieri G, Arkenau HT, Roselli M, Orlandi A. Concordance of Blood-Based and Normal Tissue- Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping. Oncologist. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057. PMID: 35325223; PMCID: PMC9075005.
  24. Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassineti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021 Nov;9(11):e002996. doi: 10.1136/jitc-2021-002996. PMID: 34815354; PMCID: PMC8611452.
  25. Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L. Results of the observational prospective RealFLOT study. BMC Cancer. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. PMID: 34625033; PMCID: PMC8499559.
  26. Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M. KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2021 Sep 20:djab190. doi: 10.1093/jnci/djab190. Epub ahead of print. PMID: 34542636.
  27. Formica V, Nardecchia A, Morelli C, Lucchetti J, Giuliano G, Renzi N, Gallo C, Pellegrino R, Massimiliani V, Serci C, Russo A, Patrikidou A, Arkenau HT, Maiorino L, Tesauro M, Roselli M. Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age. Ann Palliat Med. 2021 Apr;10(4):4252-4261. doi: 10.21037/apm-20-2194. Epub 2021 Apr 1. PMID: 33832305.
  28. Del Vecchio Blanco G, Dwairi R, Giannelli M, Palmieri G, Formica V, Portarena I, Grasso E, Di Iorio L, Benassi M, Giudice EA, Nardecchia A, Rossi P, Roselli M, Sica G, Monteleone G, Paoluzi OA. Clinical care pathway program versus open- access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer. Intern Emerg Med. 2021 Feb 8. doi: 10.1007/s11739-020-02565-z. Epub ahead of print. PMID: 33555540.
  29. Del Vecchio Blanco G, Palmieri G, Giannarelli D, Formica V, Portarena I, Nardecchia A, Troncone E, Benassi M, Giudice E, Anselmo A, Tisone G, Roselli M,Monteleone G, Paoluzi OA. Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. Scand J Gastroenterol. 2021 Feb 4:1-7. doi: 10.1080/00365521.2021.1880628. Epub ahead of print. PMID: 33539716.
  30. Bavetta M, Silvaggio D, Campione E, Sollena P, Formica V, Coletta D, Graziani G, Romano MCP, Roselli M, Peris K, Bianchi L. The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. J Clin Med. 2021 Jan 26;10(3):466. doi: 10.3390/jcm10030466. PMID: 33530427; PMCID: PMC7866016.
  31. Formica V, Lucchetti J, Doldo E, Riondino S, Morelli C, Argirò R, Renzi N, Nitti D, Nardecchia A, Dell'Aquila E, Ferroni P, Guadagni F, Palmieri G, Orlandi A, Roselli M. Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients-The Importance of Tissue/Plasma Discordant Cases. J Clin Med. 2020 Dec 29;10(1):87. doi: 10.3390/jcm10010087. PMID: 33383664; PMCID: PMC7794782.
  32. Formica V, Morelli C, Patrikidou A, Shiu KK, Nardecchia A, Lucchetti J, Roselli M, Arkenau HT. A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit Rev Oncol Hematol. 2021 Jan;157:103173. doi: 10.1016/j.critrevonc.2020.103173. Epub 2020 Nov 18. PMID: 33278677.
  33. Morelli C, Formica V, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M. Irinotecan or Oxaliplatin: Which is the First Move for the Mate? Curr Med Chem. 2020 Oct 16. doi: 10.2174/0929867327666201016124950. Epub ahead of print. PMID: 33069191.
  34. Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A, Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, Formica V, Lencioni M, Falcone A, Vasile E, Fornaro L. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Eur J Cancer. 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub 2020 Aug 1. PMID: 32750500.
  35. Formica V, Minieri M, Bernardini S, Ciotti M, D'Agostini C, Roselli M, Andreoni M, Morelli C, Parisi G, Federici M, Paganelli C, Legramante JM. Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2. Clin Med (Lond). 2020 Jul;20(4):e114-e119. doi: 10.7861/clinmed.2020-0373. Epub 2020 Jul 2. PMID: 32620590; PMCID: PMC7385801.
  36. Formica V, Morelli C, Patrikidou A, Murias C, Butt S, Nardecchia A, Lucchetti J, Renzi N, Shiu KK, Roselli M, Arkenau HT. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. Target Oncol. 2020 Jun;15(3):327-336. doi: 10.1007/s11523-020-00723-z. PMID: 32449030.
  37. Formica V, Morelli C, Patrikidou A, Shiu KK, Roselli M, Arkenau HT. Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy. Gastric Cancer. 2020 Nov;23(6):1107-1108. doi: 10.1007/s10120-020-01084-2. Epub 2020 May 18. PMID: 32424650.
  38. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. Cancers (Basel). 2020 May 6;12(5):1167. doi: 10.3390/cancers12051167. PMID: 32384641;PMCID: PMC7281278.
  39. Sibio S, Di Giorgio A, D'Ugo S, Palmieri G, Cinelli L, Formica V, Sensi B, Bagaglini G, Di Carlo S, Bellato V, Sica GS. Histotype influences emergency presentation and prognosis in colon cancer surgery. Langenbecks Arch Surg. 2019 Nov;404(7):841-851. doi: 10.1007/s00423-019-01826-6. Epub 2019 Nov 23. PMID: 31760472.
  40. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E,Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F,Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I,Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the'BRAF BeCool' study. Eur J Cancer. 2019 Sep;118:121-130. doi:10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19. PMID: 31330487.
  41. Morelli C, Formica V, Pellicori S, Menghi A, Guarino MD, Perricone R,Roselli M. Chemotherapy in Patients with Hereditary Angioedema. Anticancer Res.2018 Dec;38(12):6801-6807. doi: 10.21873/anticanres.13052. PMID: 30504393.
  42. Lucchetti J, Formica V, Giuliano G, Coletta D, Gargano L, Morosetti D,Sileri P, Palmieri G, Roselli M. Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia. Anticancer Res. 2018 Nov;38(11):6561-6564. doi: 10.21873/anticanres.13022. PMID: 30396986.
  43. Legramante JM, Pellicori S, Magrini A, Frittelli T, Formica V, Roselli M.Cancer Patients in the Emergency Department: A "Nightmare" that Might Become a Virtuous Clinical Pathway. Anticancer Res. 2018 Nov;38(11):6387-6391. doi: 10.21873/anticanres.12998. PMID: 30396962.
  44. Formica V, Zaniboni A, Loupakis F, Roselli M. Non-inferiority of three months vs six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? Int J Cancer. 2018 Jun 6. [Epub ahead of print].
  45. Cereda V, Formica V, Roselli M. Issues and promises of bevacizumab in prostate cancer treatment. Expert Opin Biol Ther. 2018 Jun;18(6):707-717.
  46. Formica V, Benassi M, Del Vecchio Blanco G, Doldo E, Martano L, Portarena I, Nardecchia A, Lucchetti J, Morelli C, Giudice E, Rossi P, Anselmo A, Sileri P, Sica G, Orlandi A, Santoni R, Roselli M. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. Med Oncol. 2018 May 2;35(6):83.
  47. Formica V, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M. Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer. Oncotarget. 2017 Dec 17;9(2):2876-2886.
  48. Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, Spila A, D'Alessandro R, Della-Morte D, Ferroni P, Roselli M. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World J Gastroenterol. 2017 Jul 28;23(28):5187-5195.
  49. Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M. Biological and predictive role of ERCC1 polymorphisms in cancer. Crit Rev Oncol Hematol. 2017 Mar;111:133-143.
  50. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017 Apr;49(4):338-358.
  51. Ferroni P, Formica V, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M. Prognostic value of glycated hemoglobin in colorectal cancer. World J Gastroenterol. 2016 Dec 7;22(45):9984-9993.
  52. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretti M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2017 Mar 1;28(3):555-561.
  53. Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pellicori S, Cereda V, Russo A, Riondino S, Guadagni F, Roselli M. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomark. 2016 Sep 26;17(3):335-345.
  54. Riondino S, Guadagni F, Formica V, Ferroni P, Roselli M. Gender Differences in Cancer-associated Venous Thromboembolism. Curr Med Chem. 2017;24(24):2589-2601.
  55. Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016 May 19;5(7):e1188243.
  56. Fiaschetti V, Liberto V, Claroni G, Loreni G, Formica V, Roselli M, Mauriello A, Floris R. Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature. Radiol Case Rep. 2016 May 14;11(3):255-9.
  57. Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist. 2016 Sep;21(9):1041-9.
  58. Formica V, Zaniboni A. Response from Drs. Formica/Zaniboni to Dr. Milano. Cancer Chemother Pharmacol. 2016 Aug;78(2):247.
  59. Zaniboni A, Formica V. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol. 2016 Aug;78(2):233-44.
  60. Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):219-28. doi: 10.4103/0971-5851.171542. PMID: 26811591; PMCID: PMC4711220.
  61. Formica V, Formica D, Formica G. The 'death pace' in the CO.17 trial. Eur J Cancer. 2016 Jan;53:1-4. doi: 10.1016/j.ejca.2015.09.020. Epub 2015 Dec 11. PMID: 26688001.
  62. Riondino S, Ferroni P, Spila A, Alessandroni J, D'Alessandro R, Formica V, Della-Morte D, Palmirotta R, Nanni U, Roselli M, Guadagni F. Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle. Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):291-9. PMID: 26543078.
  63. Lisanti A, Formica V, Ianni F, Albertini B, Marinozzi M, Sardella R, Natalini B. Antioxidant activity of phenolic extracts from different cultivars of Italian onion (Allium cepa) and relative human immune cell proliferative induction. Pharm Biol. 2016;54(5):799-806. doi: 10.3109/13880209.2015.1080733. Epub 2015 Oct 9. PMID: 26452395.
  64. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. PMID: 26446234; PMCID: PMC4718427.
  65. Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V, Guadagni F, Roselli M. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thromb Haemost. 2016 Jan;115(1):143-51. doi: 10.1160/TH15-03-0259. Epub 2015 Sep 3. PMID: 26336029.
  66. Del Vecchio Blanco G, Coppola M, Mannisi E, Bevivino G, Formica V, Portarena I, Romeo S, Sileri P, Roselli M, Pallone F, Paoluzi OA. Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass. Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1045-51.
  67. Cereda V, Formica V, Menghi A, Pellicori S, Roselli M.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. Expert Opin Investig Drugs. 2015 Jul;24(7):929-47.
  68. Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol. 2015 Mar 14;21(10):2871-4.
  69. Formica V, Montefusco E, Roselli M. Are there alternative ways to quantify the real benefit of novel agents in oncology? -the 'death pace'.Cancer Biol Ther. 2015;16(2):187-8.
  70. Formica V, Cereda V, Nardecchia A, Tesauro M, Roselli M. Immune reaction and colorectal cancer: friends or foes? World J Gastroenterol. 2014 Sep 21;20(35):12407-19.
  71. Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014 Sep;31(9):166.
  72. Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, Valente MG, Vergati M, Guadagni F, Roselli M. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.Int J Cancer. 2015 Mar 1;136(5):1234-40.
  73. Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer relationship with clinical outcome.Anticancer Res. 2014 Mar;34(3):1153-61.
  74. Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Expert Opin Investig Drugs. 2014 Apr;23(4):469-87.
  75. Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013 Oct 1;2(10):e27025.
  76. Vincenzo F, Manfredi T, Carmine C, Mario R. CD26: a multi-purpose pharmacological target. Curr Clin Pharmacol. 2014 May;9(2):157-64. doi: 10.2174/1574884708666131111201654. PMID: 24219003.
  77. Formica V, Cereda V, di Bari MG, Grenga I, Tesauro M, Raffaele P, Ferroni P, Guadagni F, Roselli M.Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Med Oncol. 2013 Dec;30(4):743.
  78. Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirotta R, Formica V, Ludovici G, Laudisi A, De Marchis ML, La Farina F, Russo A, Guadagni F. TNF-a gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Ann Oncol. 2013 Oct;24(10):2571-5.
  79. Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, Formica V, Vergati M, Guadagni F. Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. Thromb Haemost. 2012 Dec;108(6):1243-5.
  80. Formica V, Vasile E, Roselli M. Family history of cancer in patients with gastric cancer. J Clin Oncol. 2012 Sep 1;30(25):3151-2; author reply 3152-3.
  81. Palmirotta R, Ludovici G, De Marchis ML, Leone B, Formica V, Ettorre GM, Cavaliere F, Della-Morte D, Ferroni P, Roselli M, Guadagni F.A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. In Vivo. 2012 Jul;26(4):537-47.
  82. Sileri P, D'Ugo S, del Vecchio Blanco G, Lolli E, Franceschilli L, Formica V, Anemona L, De Luca C, Gaspari AL. Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case. Int J Surg Case Rep. 2012;3(8):3858.
  83. Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, Massimiani G, Palmirotta R, Guadagni F, Roselli M. Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis. 2012 Dec;27(12):1561-7.
  84. Formica V, Tesauro M, Cardillo C, Roselli M. Insulinemia and the risk of breast cancer and its relapse. Diabetes Obes Metab. 2012 Apr 26.
  85. Formica V, Martano L, Palmirotta R, Ferroni P, Del Monte G, Guadagni F, Roselli M. VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. Ann Oncol. 2011 Aug;22(8):1928-9.
  86. Formica V, Del Monte G, Giacchetti I, Grenga I, Giaquinto S, Fini M, Roselli M. Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience. Integr Cancer Ther. 2011 Jun;10(2):119-26.
  87. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis. 2011 Feb;26(2):143-51.
  88. Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. Anticancer Res. 2010 Nov;30(11):4721-30.
  89. Pellegrino R, Formica V, Portarena I, Mariotti S, Grenga I, Del Monte G, Roselli M. Caregiver distress in the early phases of cancer. Anticancer Res. 2010 Nov;30(11):4657-63.
  90. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol. 2009;122(4):193-9.
  91. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark. 2009;5(4):167-75.
  92. Palmirotta R, Savonarola A, Formica V, Ludovici G, Del Monte G, Roselli M, Guadagni F. A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Res. 2009 Aug;29(8):3369-74.
  93. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009 Aug;29(8):3321-7.
  94. Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol. 2010 Jan;8(1):102-13.
  95. Formica V, Fossile E, Pellegrino R, Fatale M, Mari M, Rabuffetti M, Benedetto FR, Visconti G, Bollero E, Roselli M. The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience. Support Care Cancer. 2009 May;17(5):471-8.
  96. Masala S, Manenti G, Roselli M, Mammucari M, Bartolucci DA, Formica V, Massari F, Simonetti G. Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol. Anticancer Res. 2007 Nov-Dec;27(6C):4259-62.
  97. Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V, Roselli M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 2007 Sep-Oct;27(5A):3147-62.
  98. Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology. 2006;71(3-4):176-84.
  99. Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V, Roselli M. Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo. 2007 Mar-Apr;21(2):147-61.
  100. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007 Apr 23;96(8):1178-82
  101. Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol. 2006 Jul;17(7):1174-5.
  102. Formica V, Leary A, Cunningham D, Chua YJ. 5-Fluorouracil can cross Brain Blood Barrier (BBB) and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol. 2006 Aug;58(2):276-8.
  103. De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection? J Clin Oncol. 2005 Sep 1;23(25):6274-5
  104. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005 Jul 15;175(2):820-8.
  105. De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nole F, Fazio N, Formica V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain Support Care Cancer. 2005 Mar;13(3):194-5.
  106. Bonmassar L, Massara MC, Cottarelli A, Aquino A, Formica V, Prete SP, Lacal PM, Marchetti P, Concolino F, Faraoni I, D'Atri S. Preclinical studies on detection of circulating melanoma cells in patients: telomerase as a recognition marker of malignancy J Chemother. 2004 Oct;16(5):479-86.
  107. Curigliano G, Rigo R, Colleoni M, Nolè F, Formica V, Orlando L, Cardillo A, Torrisi R, Manzoni S, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant Therapy for Very Young Women With Breast Cancer: Response According to Biologic and Endocrine Features. Clin Breast Cancer. 2004 Jun;5(2):125-30. Review.
  108. Aquino A, Formica V, Prete SP, Correale PP, Massara M.C, Turriziani M, De Vecchis L, Bonmassar E. Drug induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res. 2004 Apr;49(5):383-96. Review.
  109. Aquino A, Prete SP, Balduzzi A, Fossile E, Formica V, Torino F, Bonmassar L, Di Giacomo A, Cappelletti D, Cardillo A, Bonmassar E, Graziani G. A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report. J Chemother. 14:412-416, 2002.
  110. Aquino A, Prete S.P, Balduzzi A, Formica V, Fossile E, Bonmassar L, Concolino F, Bonmassar E, Graziani G. Treatment of peripheral blood with Staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. Int J Cancer. 100:119-121, 2002.

 

 a:0:{}" } ["meta_keywords"]=> array(1) { [0]=> string(1) "," } ["reserved"]=> array(1) { [0]=> string(1) "0" } ["auth_ip"]=> array(1) { [0]=> string(1) "0" } } ["_fieldBoosts":protected]=> array(6) { ["content_id"]=> bool(false) ["content_title"]=> bool(false) ["description"]=> bool(false) ["meta_keywords"]=> bool(false) ["reserved"]=> bool(false) ["auth_ip"]=> bool(false) } } }